Taysha Gene Therapies, Inc. (TSHA) earnings date
Mar 16, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 14 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | before open | 43 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | after close | 42 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Thu, Mar 19, 2026 | before open | 78 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | before open | 35 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | before open | 43 | 8-K |
| Q1 FY2025 | Thu, May 15, 2025 | before open | 45 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | before open | 57 | 8-K |
What they guided beta
| Q3 FY2026 | "Exhibit 99.1 Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff Completed BLA-enabling PPQ manufacturing campaign for TSHA-102, which met predefined product specifica" exhibit |
| Q3 FY2026 | "Looking ahead, we believe the first half of 2027 could be a transformative period for Taysha with our plan to report data from the six-month interim analysis of our REVEAL pivotal trial along with expected FDA feedback on our BLA submission pathway, and the anticipated nomination of a second gene therapy development program with a high unmet medical need and robust commercial opportunity as we begin building a broader CNS genetic medicine franchise.”" exhibit |
| Q3 FY2026 | "FDA feedback following CMC Type B meeting expected in the first quarter of 2027" exhibit |
| Q3 FY2026 | "Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027" exhibit |
| Q3 FY2026 | "Expect to nominate an additional gene therapy development candidate targeting a CNS disorder with high unmet need and commence preclinical development activities in the first half of 2027" exhibit |
| Q2 FY2026 | "Exhibit 99.1 Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff Longer-term REVEAL Part A data demonstrated broad, multi-domain functi" exhibit |
| Q2 FY2026 | "Looking ahead, with a strengthened balance sheet, we remain focused on executing our BLA-enabling activities and anticipate reporting topline data from the REVEAL pivotal trial six-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.”" exhibit |
| Q2 FY2026 | "Subsequently, Taysha plans to discuss data from the 6-month interim analysis and next steps in the BLA submission pathway with the U.S. Food and Drug Administration (FDA) and is on track to report topline data and regulatory feedback in 1H 2027." exhibit |
| Q2 FY2026 | "Completion of BLA-enabling Process Performance Qualification (PPQ) campaign for TSHA-102 is expected in the fourth quarter of 2026" exhibit |
| Q2 FY2026 | "Topline data from REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 is expected in the first half of 2027 Second Quarter 2026 Financial Highlights Research and Development Expenses: Research and development expenses were $38.6 million for the three months ended June 30, 2026, compared to $20.1 million for the three months ended June 30, 2025." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TSHA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TSHA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TSHA/"><img src="https://veritasdata.dev/embed/TSHA.svg" alt="TSHA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TSHA/)
Script
<script async src="https://veritasdata.dev/embed/TSHA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TSHA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.